LY-367,265

LY-367,265
Identifiers
	IUPAC name 1-(2-(4-(6-fluoro-1H-indol-3-yl)-5,6-dihydropyridin-1(2H)-yl)ethyl)-1,4,5,6-tetrahydro-[1,2,5]thiadiazolo[4,3,2-ij]quinoline 2,2-dioxide;
CAS Number	210751-39-6;
PubChem CID	4605800;
ChemSpider	3797242;
UNII	SS58UXZ8ZU;
ChEBI	CHEBI:183634;
CompTox Dashboard (EPA)	DTXSID801017165 ;
Chemical and physical data
Formula	C24H25FN4O2S
Molar mass	452.55 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC1=CC=C2C(NC=C2C3=CCN(CCN(S4(=O)=O)C5=C6C(CCCN46)=CC=C5)CC3)=C1;
	InChI InChI=1S/C24H25FN4O2S/c25-19-6-7-20-21(16-26-22(20)15-19)17-8-11-27(12-9-17)13-14-28-23-5-1-3-18-4-2-10-29(24(18)23)32(28,30)31/h1,3,5-8,15-16,26H,2,4,9-14H2; Key:BJIPVHLRWSDKOS-UHFFFAOYSA-N;

LY-367,265 is a drug developed by Eli Lilly, which acts as both a potent and selective antagonist at the serotonin 5-HT_2A receptor, and also a selective serotonin reuptake inhibitor (SSRI). It has antidepressant effects in animal studies, reduces glutamate signalling in the brain and increases the analgesic effects of morphine.^[1]^[2]^[3]

References

^ Pullar IA, Carney SL, Colvin EM, Lucaites VL, Nelson DL, Wedley S (October 2000). "LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone". European Journal of Pharmacology. 407 (1–2): 39–46. doi:10.1016/S0014-2999(00)00728-7. PMID 11050288.
^ Wang SJ (March 2005). "Potential antidepressant LY 367265 presynaptically inhibits the release of glutamate in rat cerebral cortex". Synapse. 55 (3): 156–63. doi:10.1002/syn.20104. PMID 15602751. S2CID 11860623.
^ Ozdemir E, Bagcivan I, Gursoy S, Altun A, Durmus N (June 2011). "Effects of fluoxetine and LY 367265 on tolerance to the analgesic effect of morphine in rats". Acta Physiologica Hungarica. 98 (2): 205–13. doi:10.1556/APhysiol.98.2011.2.12. PMID 21616779.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.